Joseph Vadakara

Clinical trials

• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2027
• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2027
• Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2027
• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2024–2029